As previously reported, Wells Fargo analyst Yanan Zhu upgraded Regulus (RGLS) to Overweight from Equal Weight with a price target of $6, up from $3, after the company announced topline results from all patients in the fourth cohort in its Phase 1b multiple ascending dose study of farabursen for the treatment of autosomal dominant polycystic kidney disease, citing consistent height-adjusted total kidney volume results now in 35 patients across multiple cohorts. This continued consistency in the htTKV data should derisk the planned Phase 3 study, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGLS:
- Regulus upgraded to Overweight from Equal Weight at Wells Fargo
- Regulus Announces Positive Phase 1b Study Results
- Regulus’ farabursen shows efficacy in Phase 1b kidney disease trial
- Promising Developments and Strategic Positioning Drive Buy Rating for Regulus Therapeutics
- Regulus Therapeutics Reports Positive Trial Results and Financials